$30MSeries A, 27 August 2025
Funds a schizophrenia study of LTX-001 and early ALS data for LTX-002.
- Amount
- $30M
- Stage
- Series A
- Announced
- 27 August 2025
- Lead
- SV Health Investors Dementia Discovery Fund
- Other investors
- OrbiMed, Newpath Partners, Chugai Venture Fund, Alexandria Venture Investments
- Use of funds
- Funds a schizophrenia study of LTX-001 and early ALS data for LTX-002.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Leal Therapeutics raises $30M Series A (date approx) pharmaceutical-business-review.com
Leal Therapeutics raises $30M Series A (date approx) news.crunchbase.com